Bluebird bio Inc [BLUE] stock is trading at $0.57, up 10.04%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BLUE shares have gain 13.01% over the last week, with a monthly amount glided 0.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on August 15, 2024, when JP Morgan downgraded its rating to a Neutral. Previously, HSBC Securities downgraded its rating to Reduce on December 11, 2023. On December 08, 2023, upgrade upgraded it’s rating to Equal-Weight and revised its price target to $7 on the stock. Cantor Fitzgerald started tracking the stock assigning a Neutral rating. HSBC Securities initiated its recommendation with a Buy and recommended $4.21 as its price target on September 06, 2023. BofA Securities upgraded its rating to Buy for this stock on July 19, 2023, and upped its price target to $10. In a note dated June 01, 2023, Barclays upgraded an Overweight rating on this stock and boosted its target price from $7 to $8.
Bluebird bio Inc [BLUE] stock has fluctuated between $0.45 and $5.53 over the past year. Currently, Wall Street analysts expect the stock to reach $14.13 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $0.57 at the most recent close of the market. An investor can expect a potential return of 2378.95% based on the average BLUE price forecast.
Analyzing the BLUE fundamentals
Bluebird bio Inc [NASDAQ:BLUE] reported sales of 54.90M for the trailing twelve months, which represents a growth of 133.69%. Gross Profit Margin for this corporation currently stands at -0.37% with Operating Profit Margin at -6.09%, Pretax Profit Margin comes in at -5.67%, and Net Profit Margin reading is -5.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -2.07 and Total Capital is -1.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 7.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5355 points at the first support level, and at 0.5011 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5897, and for the 2nd resistance point, it is at 0.6095.
Ratios To Look Out For
For context, Bluebird bio Inc’s Current Ratio is 0.68. Also, the Quick Ratio is 0.57, while the Cash Ratio stands at 0.48. Considering the valuation of this stock, the price to sales ratio is 2.01, the price to book ratio is 2.09.
Transactions by insiders
Recent insider trading involved Klima Thomas J,, that happened on Sep 30 ’24 when 1006.0 shares were sold. President and CEO, Obenshain Andrew completed a deal on Sep 30 ’24 to sell 34780.0 shares. Meanwhile, Officer Obenshain Andrew bought 34780.0 shares on Sep 30 ’24.
